Clinical trials: Niraparib
Ovarian Cancer Recurrent
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
The purpose of this study is to find out if a new drug, M4344, is safe and has beneficial effects when given in combination with the PARP inhibitor, Niraparib, in women with recurrent ovarian cancer that has progressed while on a…
- Trial name
- PARP (NCT04149145)
- Testing
- M4344+Niraparib
- Sponsor
- University of Alabama at Birmingham
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see what effects (good and bad) this combination treatment has on patients with…
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
- Trial name
- NCT05523440
- Testing
- Bevacizumab, Niraparib
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Oklahoma
SCLC,Extensive Stage, SLFN11-positive
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance.
- Trial name
- RAISE (NCT05718323)
- Testing
- Niraparib
- Where
- 18 sites in France, Germany and 3 more
- Volunteers
- 44 people
- Sponsor
- ETOP IBCSG Partners Foundation
Biliary Tract Neoplasms
Personalized Medicine for Advanced Biliary Cancer Patients
The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
- Trial name
- SAFIR-ABC10 (NCT05615818)
- Testing
- Futibatinib, Ivosidenib, Zanidatamab
- Where
- 69 sites in Belgium, France and 1 more
- Volunteers
- 800 people
- Sponsor
- UNICANCER
ATM Gene Mutation, BRCA1 Gene Mutation
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation
- Trial name
- NCT04030559
- Testing
- Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Davis
Ovarian Cancer, Peritoneal Cancer
Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR
This is a multi-centre, observational (non-interventional) study, designed to follow patients with advanced ovarian fallopian tube and primary peritoneal cancer, who are receiving Niraparib as maintenance treatment, according to…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MONITOR-UK (NCT04295577)
- Testing
- Niraparib
- Where
- 15 sites in United Kingdom
- Volunteers
- 388 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Solid Tumor, Ovarian Cancer
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
To determine the recommended phase 2 dose (RP2D) of niraparib and neratinib in combination in patients with advanced solid tumors during Phase 1.
- Trial name
- iNNOVATE (NCT04502602)
- Testing
- Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Head and Neck Cancer
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
- Trial name
- NCT04313504
- Testing
- Niraparib, Dostarlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Trisha Wise-Draper
Breast Cancer
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is…
- Trial name
- NCT05601440
- Testing
- RP-6306, Gemcitabine, Observation
- Where
- 10 sites in Canada
- Volunteers
- 484 people
- Sponsor
- Canadian Cancer Trials Group
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Prostate Cancer, Oligometastatic Disease
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of…
- Trial name
- KNIGHTS (NCT06212583)
- Testing
- niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and…
- Trial name
- ASCLEPIuS (NCT04194554)
- Testing
- Niraparib, Leuprolide, Abiraterone Acetate
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasms
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc).
- Trial name
- NCT06077877
- Testing
- GSK4524101, Niraparib
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer, Oligometastatic Disease
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in ovarian cancer (OC) patients with…
- Conditions
- Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
- Trial name
- ANALLISA (NCT06180356)
- Testing
- Niraparib oral tablets
- Where
- 14 sites in Spain
- Volunteers
- 30 people
- Sponsor
- MedSIR
Ovarian Cancer
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
The main aim of this study is to check for side effects from treatment with niraparib. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what…
- Trial name
- NCT05021562
- Testing
- Niraparib
- Where
- Japan
- Volunteers
- 354 people
- Sponsor
- Takeda
Ovarian Cancer
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual…
- Trial name
- NIRVANA-1 (NCT05183984)
- Testing
- Chemotherapy, Bevacizumab-Awwb, Niraparib
- Where
- 88 sites in France, Italy and 4 more
- Volunteers
- 390 people
- Sponsor
- ARCAGY/ GINECO GROUP
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s).
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- HARMONY (NCT06392841)
- Testing
- Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate
- Sponsor
- Qian Qin
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
- Conditions
- Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
- Trial name
- NCT05335993
- Testing
- Oregovomab, Niraparib
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- CanariaBio Inc.
Recurrent Endometrial Serous Adenocarcinoma
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent).
- Trial name
- NCT05870761
- Testing
- Biospecimen Collection, Computed Tomography, Dostarlimab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Casey Cosgrove